Grace Peace Truong

Grace Truong is an associate in Goodwin’s Intellectual Property Litigation group and a member of the firm’s Life Sciences Disputes group. She has served clients in matters involving a broad range of technologies, including pharmaceutical sciences, biotechnology, and medical devices. Her experience includes representing life science companies in litigation under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act (BPCIA), other district court patent litigation, unfair import investigations before the U.S. International Trade Commission, and proceedings before the Patent Trial and Appeal Board (PTAB).

Grace maintains an active pro bono practice, including assisting veterans in VA benefits appeals and representing clients in asylum appeals.

Grace has been involved in various stages of patent litigation, including discovery, motion practice, pretrial proceedings, and trial. Some of her recent engagements include:

• Teva Pharmaceuticals International GmbH et al. v. Eli Lilly and Company, C.A. No. 18-12029-ADB (D. Mass.). Representing Teva in asserting method of treatment patents regarding anti-CGRP antibodies against Eli Lilly’s Emgality® (galcanezumab) product.
• Certain Pre-Filled Syringes for Intravitreal Injection and Components Thereof, Inv. No. 337-TA-1207 (USITC); Novartis Pharma AG et al v. Regeneron Pharmaceuticals, Inc., C.A. No. 20-00690-DNH (N.D.N.Y.); Regeneron Pharmaceuticals, Inc. v. Novartis Pharma AG, et al., IPR2020-01317, IPR2020-01318, IPR2021-00816 (P.T.A.B.). Represented Novartis in ITC investigation and related litigations and inter partes review proceedings relating to assertion of Novartis’s pre-filled syringe patent against Regeneron’s blockbuster EYLEA® (aflibercept) product.
• Par Pharmaceutical et al. v. Amneal et al. (D. Del.). Represented Amneal Pharmaceuticals in patent infringement case involving a generic formulation of vasopressin injection.

While in law school, Grace was a student attorney in Harvard Law School’s Veterans Law and Disability Benefits Clinic and a student attorney in the Harvard Health Law and Policy Clinic. She was a line editor for Harvard Journal of Law and Technology and a Student Fellow in the Law, Science, & Technology Program. Grace was also the Events Director for the Harvard Law Entrepreneurship Project. She was awarded the Zuckerman Fellowship from the Harvard Kennedy School of Government for her public service work as a JD/MPH joint-degree student. Before joining Goodwin, Grace was an IP Litigation summer associate at Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.

Prior to attending law school, Grace was a Fulbright Fellow and a researcher at the Children’s Hospital of Philadelphia.

While attending Harvard Law, Grace received Dean’s Scholar Prize awards for outstanding work in City Use of Technology and Autonomous Vehicles and Local Government Lab.

Co-Author, “Five patent issues that European biosimilar developers should consider before entering the US market,” European Pharmaceutical Review, June 2020

Co-Author, “Call to Change,” Intellectual Property Magazine, April 2020

Grace is a contributor to Big Molecule Watch, Goodwin’s award-winning blog that reports real-time analysis and updates on regulatory issues, litigation, legislation and other news in the developing world of biosimilars. She is also a regular contributor to Goodwin’s PTAB Trial Tracker.